THE EVOLVING MOLECULAR EPIDEMIOLOGY OF HIV-1 ENVELOPE SUBTYPES IN INJECTING DRUG-USERS IN BANGKOK, THAILAND - IMPLICATIONS FOR HIV VACCINE TRIALS

Citation
Ml. Kalish et al., THE EVOLVING MOLECULAR EPIDEMIOLOGY OF HIV-1 ENVELOPE SUBTYPES IN INJECTING DRUG-USERS IN BANGKOK, THAILAND - IMPLICATIONS FOR HIV VACCINE TRIALS, AIDS, 9(8), 1995, pp. 851-857
Citations number
35
Categorie Soggetti
Immunology,"Infectious Diseases
Journal title
AIDSACNP
ISSN journal
02699370
Volume
9
Issue
8
Year of publication
1995
Pages
851 - 857
Database
ISI
SICI code
0269-9370(1995)9:8<851:TEMEOH>2.0.ZU;2-E
Abstract
Objective: To genetically characterize HIV-1 strains in injecting drug users (IDU) in Bangkok, Thailand in 1994, and compare these with stra ins found earlier in Thai IDU; such information is essential for HIV-1 vaccine development and evaluation. Methods: Peripheral blood mononuc lear cells were collected from 84 IDU attending 14 drug treatment clin ics in Bangkok in 1994. DNA was amplified using a nested polymerase ch ain reaction (PCR) procedure and sequenced directly (without cloning) from the PCR products. The V3 and flanking regions (345 nucleotides) o f the env gene were analyzed using a neighbor-joining tree. Results: O nly one (1%)strain was a typical subtype B virus, 69 (82%) were geneti cally distinct subtype B' viruses (Thai B), and 14 (17%) were subtype E strains (Thai A). Persons with recently acquired infection were more likely to have subtype E viruses (P<0.001) than those in our 1991 sur vey, who were more likely to have subtype B' viruses. Pairwise intra-s ubtype differences within subtypes E and B' were 5.3 and 4.3%, respect ively, compared with 3.4 and 3.5% among strains collected in 1991 in T hailand. Conclusion: The genetic diversity within subtypes B' and E in Thailand and the proportion of new infections due to subtype E viruse s among Bangkok IDU are increasing significantly. These data highlight the importance of monitoring the molecular epidemiology of HIV-1 in p opulations being considered for HIV-1 vaccine trials.